Population pharmacokinetics of caspofungin in critically ill patients receiving extracorporeal membrane oxygenation—an ASAP ECMO study
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01435-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Mohd H Abdul-Aziz und 14 weiteren Autor:innen. Beteiligte Einrichtung: University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Extracorporeal Membrane Oxygenation, Antifungal Agents, Echinocandins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Prince Charles Hospital Research Foundation, Australian and New Zealand College of Anaesthetists (ANZCA), Society of Hospital Pharmacists of Australia (SHPA).
Abstract (Originalsprache)
This study aimed to describe the population pharmacokinetics of caspofungin in critically ill patients receiving extracorporeal membrane oxygenation (ECMO) and to identify dosing regimens with a high likelihood of achieving effective exposures. Serial blood samples were collected over a single-dosing interval during ECMO. Total plasma concentrations were measured by a validated chromatographic assay. A population pharmacokinetic model was built and Monte Carlo dosing simulations were performed using Monolix. The probability of target attainment (PTA) and fractional target attainment (FTA) rates were simulated for various caspofungin dosing regimens against Candida albicans , Candida glabrata , and Candida parapsilosis . In all, 64 plasma concentration-time points were obtained from 8 critically ill patients receiving ECMO. Plasma concentration-time data for caspofungin were best described by a one-compartment model with first-order elimination. Lean body weight was identified as a significant covariate of volume of distribution. The typical volume of distribution and clearance of caspofungin in this cohort were 8.13 L and 0.55 L/h, respectively. The licensed caspofungin dosing regimen (a loading dose of 70 mg on day 1 followed by a maintenance dose of either 50 mg/day or 70 mg/day) demonstrated optimal PTA rates (≥90%) against C. albicans with an MIC of ≤0.064 mg/L, C. glabrata with an MIC of ≤0.125 mg/L, and C. parapsilosis with an MIC of ≤0.064 mg/L. The FTA analysis suggested that the licensed dosing regimen is only optimal (≥95%) against Candida glabrata , regardless of lean body weight. A higher-than-standard empirical dosing regimen (e.g., a loading dose of 100 mg on day 1, followed by a maintenance dose of 100 mg daily) is likely advantageous for critically ill patients receiving ECMO.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
- Department of Clinical Pharmacy, Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam, Malaysia.
- Department of Intensive Care and Hyperbaric Medicine, The Alfred Hospital, Melbourne, Victoria, Australia.
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
- Critical Care Research Group and Adult Intensive Care Services, The Prince Charles Hospital, Brisbane, Queensland, Australia.
- Cardiothoracic and Vascular Intensive Care Unit, Auckland City Hospital, Auckland, New Zealand.
ORCID-Profile: Mohd H Abdul-Aziz
Förderung
- The Prince Charles Hospital Research Foundation
- Australian and New Zealand College of Anaesthetists (ANZCA)
- Society of Hospital Pharmacists of Australia (SHPA)
- DHAC | National Health and Medical Research Council (NHMRC)
Zitieren
APA
Abdul-Aziz, M. H., Diehl, A., Liu, X., Cheng, V., Corley, A., Gilder, E., Levkovich, B., McGuinness, S., Ordonez, J., Parke, R., Pellegrino, V., Wallis, S. C., Fraser, J. F., Shekar, K., & Roberts, J. A. (2025). Population pharmacokinetics of caspofungin in critically ill patients receiving extracorporeal membrane oxygenation—an ASAP ECMO study. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01435-24
Vancouver
Abdul-Aziz MH, Diehl A, Liu X, Cheng V, Corley A, Gilder E, et al. Population pharmacokinetics of caspofungin in critically ill patients receiving extracorporeal membrane oxygenation—an ASAP ECMO study. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01435-24
BibTeX
@article{AbdulAziz2025,
author = {Abdul-Aziz, Mohd H and Diehl, Arne and Liu, Xin and Cheng, Vesa and Corley, Amanda and Gilder, Eileen and Levkovich, Bianca and McGuinness, Shay and Ordonez, Jenny and Parke, Rachael and Pellegrino, Vincent and Wallis, Steven C and Fraser, John F and Shekar, Kiran and Roberts, Jason A},
title = {Population pharmacokinetics of caspofungin in critically ill patients receiving extracorporeal membrane oxygenation—an ASAP ECMO study},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01435-24}
}
EUVIMED